Exchange: NASDAQ·Updated 07:33 PM EDT

CRMD News

News
all
press releases
CorMedix (CRMD) Upgraded to Buy: Here's Why
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Biotech Momentum Meets a Google AI Shockwave: 4 Stocks Traders Are Watching Now
Biotech momentum is carrying forward, as the three biotechs we covered, Picard Medical (NYSEAMERICAN:PMI), NeOnc Technologies (NASDAQ:NTHI), and CorMedix (NASDAQ:CRMD) continue to move, while Rezolve Ai (NASDAQ:RZLV) has introduced a powerful new AI infrastructure catalyst through Google (NASDAQ:GOOG).
24-7 Market News
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
These Stocks are Keeping the Heat Up
The market is once again rewarding companies that can produce a combination of real operating progress, identifiable catalysts and a credible path to growth, including NeOnc (NASDAQ:NTHI), Profusa (NASDAQ:PFSA), CorMedix (NASDAQ:CRMD), IP Strategy (NASDAQ:IPST), Haemonetics (NYSE:HAE), Heartflow (NASDAQ:HTFL), and FreeCast (NASDAQ:CAST).
24-7 Market News
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
Zacks
CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat
CorMedix expects to submit its supplemental Rezzayo application in Q3, with a potential FDA decision in the first half of 2027.
Stocktwits
The Stocks Suddenly Giving Traders Something to Chase
The market is delivering a potent mix of earnings acceleration and fresh corporate catalysts can quickly reshape investor expectations. $CRMD, $XHG, $IVDA, $DFSC, $FGI, $ARX
24-7 Market News
CorMedix Is Printing Cash: CRMD Drops $101.9M Quarter as DefenCath Takes Off
CorMedix Therapeutics (NASDAQ:CRMD) just delivered another powerful quarter, pairing $101.9 million in Q2 revenue with $58.7 million in adjusted EBITDA while expanding DefenCath’s commercial reach and preparing for a potentially major REZZAYO label expansion.
24-7 Market News
Full Transcript: Cormedix Q2 2026 Earnings Call
On Thursday, Cormedix (NASDAQ:CRMD) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial dataread more...
Benzinga

Advertisement|Remove ads.